Tech Transfer eNews Blog

AuraVax licenses tech from Massachusetts General Hospital to enhance respiratory illness vaccines, including COVID-19

By Jesse Schwartz
Published: January 20th, 2021

Vaccine developer AuraVax has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) to advance a technology aimed at enhancing vaccines for COVID-19 and other respiratory illnesses.

Developed by MGH researcher Mei X. Wu, the technology is a safe and potent adjuvant that can be delivered intranasally to boost the effectiveness of vaccines against, influenza, COVID, and other respiratory viruses.

“We are delighted to be collaborating with MGH and Dr. Wu,” says Navin Varadarajan, co-founder of AuraVax. “The intellectual property expands our portfolio to broadly target respiratory diseases from both a vaccine and therapeutic perspective. We plan to stop COVID-19, a respiratory virus, at its point of entry — the nasal cavity — as well as provide systemic protection.”

“The immediate challenge presented by COVID-19 and the stunning science that has emerged related to the virus have enriched our knowledge about the immune response,” Wu comments. “There is evidence that triggering a mucosal immune response can evoke rapid and durable protection against pandemic viruses, such as SARS-CoV-2, and through this collaboration with AuraVax, we look forward to pursuing this approach.”

“The urgent race for more effective ways of vaccinating against COVID-19 and other diseases has led to a broad and extensive focus on various protective mechanisms of action,” adds Varadarajan. “Based on pre-clinical work, our approach not only elicits a mucosal immune response, but also systemic immunity. We believe AuraVax has a competitive advantage given the platform’s ability to generate localized and generalized immune responses and a technology that simplifies the supply chain, making it well-suited for widespread distribution and self-administration.”

Source: Cision

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment